Abstract:Pharmaceutical cocrystals can offer another advanced strategy for drug preparation and development and can facilitate improvements to the physicochemical properties of active pharmaceutical ingredients (APIs) without altering their chemical structures and corresponding pharmacological activities. Therefore, cocrystals show a great deal of potential in the development and research of drugs. In this work, pharmaceutical cocrystals of ethenzamide (ETZ) with 2,6-dihydroxybenzoic acid (26DHBA), 2,4-dihydroxybenzoic acid (24DHBA) and gallic acid (GA) were synthesized by the solvent evaporation method. In order to gain a deeper understanding of the structural changes after ETZ cocrystallization, terahertz time domain spectroscopy (THz-TDS) and Raman spectroscopy were used to characterize the single starting samples, corresponding physical mixtures and the cocrystals. In addition, the possible molecular structures of ETZ-GA, ETZ-26DHBA and ETZ-24DHBA cocrystals were optimized by density functional theory (DFT). The results of THz and Raman spectra with the DFT simulations for the three cocrystals revealed that the ETZ-GA cocrystal formed an O-H∙∙∙O hydrogen bond between the -OH of GA and oxygen of the amide group of the ETZ molecule, and it was also found that ETZ formed a dimer through a supramolecular amide-amide homosynthon; meanwhile, the ETZ-26DHBA cocrystal was formed by a powerful supramolecular acid-amide heterosynthon, and the ETZ-24DHBA cocrystal formed the O-H∙∙∙O hydrogen bond between the 4-hydroxy group of 24DHBA and oxygen of the amide group of the ETZ molecule. It could be seen that in the molecular structure analysis of the three cocrystals, the position and number of hydroxyl groups in the coformers play an essential role in guiding the formation of specific supramolecular synthons.

Novel cocrystals of agomelatine, synthesis method thereof and pharmaceutical compositions containing same

Improving the Solubility of Agomelatine Via Cocrystals

New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it

Structures of polymorphic agomelatine and its cocrystals with acetic acid and ethylene glycol

Development of a Novel Amorphous Agomelatine Formulation With Improved Storage Stability and Enhanced Bioavailability

Pharmaceutical Cocrystals: A Novel Systematic Approach for the Administration of Existing Drugs in New Crystalline Form

Development of agomelatine nanocomposite formulations by wet media milling

Influence of Temperature, Solvents, and Excipients on Crystal Transformation of Agomelatine

Introduction of Synthesis Method of Agomelatine

Novel Glutaric Acid Cocrystal Formation Via Cogrinding and Solution Crystallization

Synthesis and structural analysis of pharmaceutical co-crystals

Quantification and structural elucidation of potential impurities in agomelatine active pharmaceutical ingredient.

Preparation and Characterization of Novel Pharmaceutical Co-Crystals: Ticagrelor with Nicotinamide

Synthesis and Characterization of Nano-Sized 4-Aminosalicylic Acid-Sulfamethazine Cocrystals

A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide

Pharmaceutical properties of two ethenzamide-gentisic acid cocrystal polymorphs: Drug release profiles, spectroscopic studies and theoretical calculations

Pharmaceutical cocrystal consisting of ascorbic acid with p-aminobenzoic acid and paracetamol

Dimemorfan phosphate crystal form II and preparation method thereof, and pharmaceutical composition

Pharmaceutical Cocrystals of Ethenzamide: Molecular Structure Analysis Based on Vibrational Spectra and DFT Calculations

Obtaining Cocrystals by Reaction Crystallization Method: Pharmaceutical Applications

LC-MS/MS Method for the Determination of Agomelatine in Human Plasma and Its Application to a Pharmacokinetic Study.